SCHEMBL3586319

SCHEMBL3586319

N#Cc1ccc(CNc2nc(-c3cccs3)cc(-c3ccoc3)c2C#N)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 4/20 0.43
▸ ADORA1 P30542 3/20 0.43
▸ KMT2A Q03164 4/20 0.41
▸ PIM1 P11309 1/20 0.41
▸ ALDH1A1 P00352 9/20 0.40
▸ KDM4E B2RXH2 6/20 0.40
▸ HPGD P15428 6/20 0.40
▸ GAA P10253 5/20 0.40
▸ CYP1A2 P05177 3/20 0.40
▸ CYP3A4 P08684 3/20 0.40
▸ CYP2D6 P10635 3/20 0.40
▸ CYP2C9 P11712 3/20 0.40
▸ CYP2C19 P33261 3/20 0.40
▸ TDP1 Q9NUW8 2/20 0.40
▸ NPSR1 Q6W5P4 2/20 0.40
▸ CLK4 Q9HAZ1 2/20 0.40
▸ ADORA2B P29275 1/20 0.40
▸ USP2 O75604 1/20 0.40
▸ KAT8 Q9H7Z6 1/20 0.40
▸ MEN1 O00255 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14390999 0.92 ADORA1 (0.47) ADORA2AADORA1KMT2APIM1ALDH1A1
SCHEMBL13545959 0.89 ALDH1A1 (0.49) ADORA2AADORA1KMT2APIM1ALDH1A1
SCHEMBL3594245 0.88 PDE5A (0.47) ADORA2AADORA1KMT2APIM1ALDH1A1
SCHEMBL3588667 0.88 KDM4E (0.45) ADORA2AADORA1KMT2APIM1ALDH1A1
SCHEMBL13545960 0.86 MAPT (0.48) ADORA2AADORA1KMT2APIM1ALDH1A1
SCHEMBL3594042 0.86 CYP2C19 (0.43) ADORA2AADORA1KMT2APIM1ALDH1A1
SCHEMBL3599988 0.86 ALDH1A1 (0.43) ADORA2AADORA1KMT2AALDH1A1KDM4E
SCHEMBL13545955 0.85 ADORA2A (0.38) ADORA2AADORA1KMT2APIM1ALDH1A1
SCHEMBL13545961 0.84 ADORA2A (0.60) ADORA2AADORA1KMT2APIM1ALDH1A1
SCHEMBL13545953 0.82 ALDH1A1 (0.48) ADORA2AADORA1KMT2APIM1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100009973-A1 Integrase Inhibitors 3 AVEXA LIMITED (AU) 2010-01-14 — — US disclosed
US-20100009973-A1 Integrase Inhibitors 3 AVEXA LIMITED (AU) 2010-01-14 — — US disclosed
US-20100009973-A1 Integrase Inhibitors 3 AVEXA LIMITED (AU) 2010-01-14 — — US disclosed
EP-2019827-A1 INTEGRASE INHIBITORS 3 Avexa Limited (AU) 2009-02-04 — — EP disclosed
WO-2007124546-A1 INTEGRASE INHIBITORS 3 AVEXA LIMITED (AU) 2007-11-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009973-A1 Integrase Inhibitors 3 TYMP, IMPDH1, IMPDH2 ADORA2A 3605/4885ADORA1 2470/4885KMT2A 728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback